No effect of human chorionic gonadotropin treatment due to threatened abortion in early pregnancy for birth outcomes

Open Medicine ◽  
2008 ◽  
Vol 3 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Andrew Czeizel ◽  
István Dudás ◽  
János Gidai ◽  
Erzsébet Horváth-Puhó
Keyword(s):  
Preterm Birth ◽  
Pregnant Women ◽  
Spontaneous Abortion ◽  
Chorionic Gonadotropin ◽  
Early Pregnancy ◽  
Human Chorionic Gonadotropin ◽  
Low Birthweight ◽  
Preterm Births ◽  
Data Set ◽  
Threatened Abortion

AbstractHuman chorionic gonadotropin (HCG) is used parenterally for treatment of threatened abortions and repeated spontaneous abortion in pregnant women. No controlled epidemiological studies of preterm birth and low birthweight newborns in pregnant women with HCG treatment have been published while the results of animal investigations were controversial. The data of 97 pregnant women with HCG treatment in the second and third months of pregnancy due to threatened abortion and/or previous spontaneous abortion(s) was compared with the data of other 38,054 pregnant women in the population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities. There was no difference in mean gestational age at delivery and birth weight, in addition the rate of preterm birth and low birthweight newborns. Parenteral HCG treatment in the early pregnancy due to threatened abortion did not associate with a higher risk for preterm births or low birthweight newborns. However, a higher occurrence of gestational diabetes was found in pregnant women with HCG treatment and there was a slight male excess among newborn infants (p=0.06).

Serum Progesterone, 17α-Hydroxyprogesterone, Human Chorionic Gonadotropin, and Prolactin in Early Pregnancy and a Case of Spontaneous Abortion

1981 ◽  
Vol 36 (1) ◽  
pp. 55-60 ◽  
Author(s):  
Paul D. Manganiello ◽  
Stanley J. Nazian ◽  
James O. Ellegood ◽  
Paul G. McDonough ◽  
Virendra B. Mahesh
Keyword(s):  
Spontaneous Abortion ◽  
Chorionic Gonadotropin ◽  
Early Pregnancy ◽  
Human Chorionic Gonadotropin ◽  
Serum Progesterone

scholarly journals Birth Outcomes of Newborns after Folic Acid Supplementation in Pregnant Women with Early and Late Pre-Eclampsia: A Population-Based Study

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Ferenc Bánhidy ◽  
Abdallah Dakhlaoui ◽  
István Dudás ◽  
Andrew E. Czeizel
Keyword(s):  
Folic Acid ◽  
Preterm Birth ◽  
Pregnant Women ◽  
Birth Outcomes ◽  
Early Pregnancy ◽  
Early Onset ◽  
Low Birthweight ◽  
Late Onset ◽  
Folic Acid Supplementation ◽  
Acid Supplementation

Objective. To evaluate the rate of preterm birth and low birth weight in the newborns of pregnant women with early and late onset pre-eclampsia according to folic acid supplementation.Study design. Birth outcomes of newborns were evaluated in 1,017 (2.7%) pregnant women with medically recorded pre-eclampsia and 37,134 pregnant women without pre-eclampsia as reference in the Hungarian Case-Control Surveillance System of Congenital Abnormalities, 1980–1996, in addition these study groups were differentiated according to the supplementation of high dose of folic acid alone from early pregnancy.Results. Pregnant women with pre-eclampsia associated with a higher rate of preterm birth (10.2% versus 9.1%) and low birthweight (7.9% versus 5.6%). There was a lower risk of preterm birth (6.8%) of newborn infants born to pregnant women with early onset pre-eclampsia after folic acid supplementation from early pregnancy though the rate of low birthweight was not reduced significantly. There was no significant reduction in the rate of preterm birth and low birthweight in pregnant women with late onset pre-eclampsia after folic acid supplementation.Conclusion. The rate of preterm birth in pregnant women with early onset pre-eclampsia was reduced moderately by high doses of folic acid supplementation from early pregnancy.

Pregnancy and obstetric complications in women with autoimmune diseases

2021 ◽  
pp. 125-142
Author(s):  
D. Ware Branch
Keyword(s):  
Menstrual Cycle ◽  
Autoimmune Diseases ◽  
Chorionic Gonadotropin ◽  
Early Pregnancy ◽  
Human Chorionic Gonadotropin ◽  
Normal Pregnancy ◽  
Obstetric Complications ◽  
Optimal Management ◽  
Foetal Development ◽  
Rheumatic Conditions

For most women, pregnancy is suspected when the symptoms of early pregnancy develop—these include breast soreness or tenderness, fatigue, nausea, and missed menses. Human chorionic gonadotropin (hCG) is first detectable using sensitive tests in the urine and blood of pregnant women 8–10 days after conception (day 22–24 of a 28-day menstrual cycle). Concentrations of hCG rise rapidly in early pregnancy, peak at 9–10 weeks, and decline thereafter to a nadir at 20 weeks. Understanding embryo-foetal development and maternal physiological accommodation to pregnancy is required for the optimal management of pregnancy in women with autoimmune diseases. This chapter reviews the important developmental and physiologic aspects of normal pregnancy and both common and unique obstetric complications associated with selected rheumatic conditions.

Human Chorionic Gonadotropin and the Diagnosis of Early Pregnancy

2010 ◽  
pp. 426-428
Author(s):  
Rene B. Allen ◽  
Mario J. Pineda ◽  
Frank Z. Stanczyk ◽  
Richard J. Paulson
Keyword(s):  
Chorionic Gonadotropin ◽  
Early Pregnancy ◽  
Human Chorionic Gonadotropin
Sign in / Sign up

Export Citation Format

Share Document